Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

296 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial.
Damaj G, Gressin R, Bouabdallah K, Cartron G, Choufi B, Gyan E, Banos A, Jaccard A, Park S, Tournilhac O, Schiano-de Collela JM, Voillat L, Joly B, Le Gouill S, Saad A, Cony-Makhoul P, Vilque JP, Sanhes L, Schmidt-Tanguy A, Bubenheim M, Houot R, Diouf M, Marolleau JP, Béné MC, Martin A, Lamy T. Damaj G, et al. Among authors: lamy t. J Clin Oncol. 2013 Jan 1;31(1):104-10. doi: 10.1200/JCO.2012.43.7285. Epub 2012 Oct 29. J Clin Oncol. 2013. PMID: 23109692 Clinical Trial.
Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trial.
Hunault M, Harousseau JL, Delain M, Truchan-Graczyk M, Cahn JY, Witz F, Lamy T, Pignon B, Jouet JP, Garidi R, Caillot D, Berthou C, Guyotat D, Sadoun A, Sotto JJ, Lioure B, Casassus P, Solal-Celigny P, Stalnikiewicz L, Audhuy B, Blanchet O, Baranger L, Béné MC, Ifrah N; GOELAMS (Groupe Ouest-Est des Leucémies Airguës et Maladies du Sang) Group. Hunault M, et al. Among authors: lamy t. Blood. 2004 Nov 15;104(10):3028-37. doi: 10.1182/blood-2003-10-3560. Epub 2004 Jul 15. Blood. 2004. PMID: 15256423 Free article. Clinical Trial.
Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study.
Choquet S, Leblond V, Herbrecht R, Socié G, Stoppa AM, Vandenberghe P, Fischer A, Morschhauser F, Salles G, Feremans W, Vilmer E, Peraldi MN, Lang P, Lebranchu Y, Oksenhendler E, Garnier JL, Lamy T, Jaccard A, Ferrant A, Offner F, Hermine O, Moreau A, Fafi-Kremer S, Morand P, Chatenoud L, Berriot-Varoqueaux N, Bergougnoux L, Milpied N. Choquet S, et al. Among authors: lamy t. Blood. 2006 Apr 15;107(8):3053-7. doi: 10.1182/blood-2005-01-0377. Epub 2005 Oct 27. Blood. 2006. PMID: 16254143 Free article. Clinical Trial.
High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial.
Canioni D, Salles G, Mounier N, Brousse N, Keuppens M, Morchhauser F, Lamy T, Sonet A, Rousselet MC, Foussard C, Xerri L. Canioni D, et al. Among authors: lamy t. J Clin Oncol. 2008 Jan 20;26(3):440-6. doi: 10.1200/JCO.2007.12.8298. Epub 2007 Dec 17. J Clin Oncol. 2008. PMID: 18086798 Clinical Trial.
Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials.
Harousseau JL, Avet-Loiseau H, Attal M, Charbonnel C, Garban F, Hulin C, Michallet M, Facon T, Garderet L, Marit G, Ketterer N, Lamy T, Voillat L, Guilhot F, Doyen C, Mathiot C, Moreau P. Harousseau JL, et al. Among authors: lamy t. J Clin Oncol. 2009 Dec 1;27(34):5720-6. doi: 10.1200/JCO.2008.21.1060. Epub 2009 Oct 13. J Clin Oncol. 2009. PMID: 19826130
Front-line high-dose chemotherapy with rituximab showed excellent long-term survival in adults with aggressive large b-cell lymphoma: final results of a Phase II GOELAMS Study.
Dilhuydy MS, Lamy T, Foussard C, Gressin R, Casassus P, Deconninck E, Le Maignan C, Damotte D, Milpied N; Groupe Ouest-Est des Leucémies et Autres Maladies du Sang (GOELAMS). Dilhuydy MS, et al. Among authors: lamy t. Biol Blood Marrow Transplant. 2010 May;16(5):672-7. doi: 10.1016/j.bbmt.2009.12.530. Epub 2010 Jan 4. Biol Blood Marrow Transplant. 2010. PMID: 20045738 Free article. Clinical Trial.
Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed mantle cell lymphoma. Combined results of two prospective phase II trials from the French GOELAMS group.
Gressin R, Caulet-Maugendre S, Deconinck E, Tournilhac O, Gyan E, Moles MP, El Yamani A, Cornillon J, Rossi JF, Le Gouill S, Lepeu G, Damaj G, Celigny PS, Maisonneuve H, Corront B, Vilque JP, Casassus P, Lamy T, Colonna M, Colombat P; French GOELAMS Group. Gressin R, et al. Among authors: lamy t. Haematologica. 2010 Aug;95(8):1350-7. doi: 10.3324/haematol.2009.011759. Epub 2010 Mar 10. Haematologica. 2010. PMID: 20220059 Free PMC article. Clinical Trial.
Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95.
Simon A, Peoch M, Casassus P, Deconinck E, Colombat P, Desablens B, Tournilhac O, Eghbali H, Foussard C, Jaubert J, Vilque JP, Rossi JF, Lucas V, Delwail V, Thyss A, Maloisel F, Milpied N, le Gouill S, Lamy T, Gressin R. Simon A, et al. Among authors: lamy t. Br J Haematol. 2010 Oct;151(2):159-66. doi: 10.1111/j.1365-2141.2010.08329.x. Epub 2010 Aug 25. Br J Haematol. 2010. PMID: 20738307 Free article. Clinical Trial.
Cutaneous macroglobulinosis treated with bortezomib and rituximab.
Marchand T, Tas P, Houot R, Dauriac C, Lamy T, Cahu X. Marchand T, et al. Among authors: lamy t. Eur J Haematol. 2011 Jul;87(1):98. doi: 10.1111/j.1600-0609.2011.01610.x. Epub 2011 May 25. Eur J Haematol. 2011. PMID: 21418108 No abstract available.
296 results